



Ifu

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 97,078-O)

PATENT

In re Application of: )

Gocke et al. )

Serial No.: 10/646,397 )

Filed: August 22, 3003 )

For: Detection of Extracellular Tumor- )  
Associated Nucleic Acid in Blood )  
Plasma or Serum Using Nucleic )  
Acid Amplification Assay )

Before the Examiner: Unassigned

Group Art Unit: 1637

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

**TRANSMITTAL LETTER**

1. We are transmitting herewith the attached papers for the above-described patent application: Information Disclosure Statement and return postcard.
2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 21, 2005.

Respectfully submitted,  
McDonnell Boehnen Hulbert & Berghoff

Dated: September 29, 2006

By:   
Donald L. Zuhn, Ph.D.  
Reg. No. 48,710



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 97,078-O)

PATENT

In re Application of: )  
)  
Gocke et al. )  
)  
Serial No.: 10/646,397 ) Before the Examiner: Unassigned  
)  
Filed: August 22, 3003 ) Group Art Unit: 1637  
)  
For: Detection of Extracellular Tumor- )  
Associated Nucleic Acid in Blood )  
Plasma or Serum Using Nucleic )  
Acid Amplification Assay )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

This statement is filed under 37 C.F.R. §§ 1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, Applicants hereby authorize the Commissioner to charge the fee to Deposit Account No. 13-2490.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff**

Dated: September 29, 2006

By: \_\_\_\_\_

Kevin E. Noonan, Ph.D.

Reg. No. 48,710

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
97,078-O

Serial No.  
10/646,397

INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT



Applicant: Gocke et al.

Filing Date:  
08/22/2003

Group: 1637

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Filing Date if Appropriate
	5 5 1 2 4 3 9	4-30-96	Hornes	
	6 0 9 0 5 6 6	7-18-00	Vogelstein	
	3 6 7 1 3	5-23-00	Vogelstein	
	5 5 1 2 4 4 1	4-30-96	Ronai	
	5 4 9 6 6 9 9	3-5-96	Sorenson	
	4 9 6 5 1 8 8	10-23-90	Mullis	
	5 5 2 7 6 7 6	6-18-96	Vogelstein	
	5 7 0 5 6 2 7		Manos	
	5 6 3 9 8 7 1		Bauer	
	5 5 2 7 8 9 8		Bauer	
	5 2 8 3 8 9 8		Manos	
	5 1 8 2 3 7 7		Manos	
	5 8 1 4 4 4 8		Silverstein	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
97,078-O

Serial No.  
10/646,397

INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT

Applicant: Gocke et al.

Filing Date:  
08/22/2003

Group: 1637

FOREIGN PATENT DOCUMENTS

		Document Number								Date	Country	Class	Subclass	Translation	
														Yes	No
	1	WO	95	1	6	7	9	2	6/22/96						
	2	WO	89	0	0	2	0	6	11/12/89						
	3	WO	97	3	4	0	1	5	09/18/97						
	4	WO	96	1	5	1	3	9	05/23/96						

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY</b> <b>APPLICANT</b>	<b>Atty. Docket No.</b> 97,078-O	<b>Serial No.</b> 10/646,397
	<b>Applicant: Gocke et al.</b>	
	<b>Filing Date:</b> 08/22/2003	<b>Group: 1637</b>

### OTHER DOCUMENTS

5	Aggarwal, et al., (March 1975) "Cell-Surface-Associated Nucleic Acid in Tumorigenic Cells Made Visible with Platinum-Pyrimidine Complexes by Electron Microscopy." <i>Proc. Nat. Acad. Sci.</i> , Vol. 72, No. 3, pp. 928-932
6	Aoki et al., (September 1995) "Liposome-mediated <i>in vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity." <i>Cancer Research</i> , 55:3810-3816
7	Ausuker et al., Editions Short Protocols in Molecular Biology John Wiley & Sons, New. York pp. 72-80, 1989.
8	Barz et al., (1985) "Characterization of cellular and extracellular plasma membrane vesicles from a non-metastasizing lymphoma (Eb) and its metastasizing variant (EESb)." <i>Biochimica et Biophysica Acta</i> , 814:7-84
9	Blackburn et al., (1991) "Electrochemiluminescence Detection of Immunoassays and DNA Probe Assays for Clinical Diagnostics." <i>Clin. Chem.</i> , Vol. 37, No. 9, pp. 1534-1539
10	Bobo et al., (September 1990) "Diagnosis of Chlamydia trachomatis Cervical Infection by Detection of Amplified DNA with and Enzyme Immunoassay." <i>Journal of Clinical Microbiology</i> , Vol. 28, No. 9, 1968-973
11	Boland, Richard, (September 1996) "Setting microsatellites free" <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 972-974
12	Boom et al., (March 1990) "Rapid and Simple Method for Purification of Nucleic Acids." <i>Journal of Clinical Microbiology</i> , Vol. 28, No. 3, pp. 495-303
13	Boom et al., (September 1991) "Rapid Purification of Hepatitis B Virus DNA from Serum." <i>Journal of Clinical Microbiology</i> , Vol. 29, No. 9, pp. 1804-1811
14	Bos et al., (May 1987) "Prevalence of ras gene mutations in human colorectal cancers." <i>Nature</i> , Vol. 327, pp. 293-297
15	Carr et al., (November 1985) "Circulating Membrane Vesicles In Leukemic Blood." <i>Cancer Research</i> , 45: 5944-5951
16	Chaubert et al., (1994) "K-ras Mutations and p53 Alterations in Neoplastic and Nonneoplastic Lesions Associated with Longstanding Ulcerative Colitis." <i>Amer. Jrnl. Of Path.</i> , Vol. 144, No. 4, pp. 767-774
17	Chen et al., (1991) "A Method to Detect ras Point Mutations in Small Subpopulations of Cells." <i>Analytical Biochemistry</i> , 195: 51-56
18	Chen et al., (September 1996) "Microsatellite alterations in plasma DNA of small cell lung cancer patients." <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 1033-1035.
19	Chen et al., "Detecting Tumor-related Alterations in Plasma or Serum DNA of patients Diagnosed with Breast Cancer," <i>Clinical Cancer Research</i> , September 1999 vol. 5, 2297-2302.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY</b> <b>APPLICANT</b>	<b>Atty. Docket No.</b> 97,078-O	<b>Serial No.</b> 10/646,397
	<b>Applicant: Gocke et al.</b>	
	<b>Filing Date:</b> 08/22/2003	<b>Group: 1637</b>

20	Cheung et al., (October 1994) "Rapid and Sensitive Method for Detection of Hepatitis C Virus RNA by Using Silica Particles." Vol. 32, No. 10, pp. 2593-2597
21	Chomczynski, Piotr, (1993) "A Reagent For the Single-Step Simultaneous Isolation of RNA, DNA and Proteins from Cell and Tissue Samples." <i>Biotechniques</i> , Vol. 15, No. 3, pp. 532-536
22	Christa et al., (1992) "Nested polymerase chain reaction of cellular DNA in plasma: a rapid method to investigate the collagen type I A2 MspI polymorphic restriction site in alcoholic patients." <i>Human Genetics</i> , 88: 537-540
23	Chua et al., 1996, <i>Int. J. Cancer</i> , 69: 54-59
24	Cleary et al., "Cloning and Structural Analysis of cDNAs for bcl-2 and a Hybrid bcl-2/Immunoglobulin Transcript Resulting from the t(14;18) Translocation," <i>Cell</i> , 47:19-28, October 10, 1985.
25	Coutlee et al., (1989) "Immunodetection of DNA with Biotinylated RNA Probes: A Study of Reactivity of a Monoclonal Antibody to DNA-RNA Hybrids." <i>Analytical Biochemistry</i> , 181: 96-105
26	DiCesare et al., (1993) "A High-Sensitivity Electrochemiluminescence-Based Detection System for Automated PCR Product Quantitation." <i>BioTechniques</i> , Vol. 15, No. 1, pp. 152-157
27	Emanuel et al., (1993) "Amplification of Specific Gene Products from Human Serum." <i>GATA</i> , Vol. 10, No. 6, pp. 144-146
28	Fearon et al., (June 1990) "A Genetic Model for Colorectal Tumorigenesis." <i>Cell</i> , Vol. 61, pp. 759-767
29	Fearon et al., (October 1987) "Clonal Analysis of Human Colorectal Tumors." <i>Science</i> , Vol. 238, pp. 193-196
30	Fedorov et al., (1987) "DNA Assay In Human Blood Plasma. Translated from <i>Byulleten Eksperimentel Biologii i Meditsiny</i> , Vol. 102, No. 9, pp. 281-281
31	Fey et al., (1991) "The Polymerase Chain Reaction: A New Tool for the Detection of minimal Residual Disease In Haematological Malignancies." <i>Eur. J. Cancer</i> , Vol. 27, No. 1, pp. 89-94
32	Finney et al., (June 1993) "Predisposition of Neoplastic Transformation Caused by Gene Replacement of H-ras1." <i>Science</i> , Vol. 260, pp. 1524-1527
33	Fournie et al., (1986) "Recovery of Nanogram Quantities of DNA from Plasma and Quantitative Measurement Using Labeling by Nick Translation." <i>Analytical Biochemistry</i> , 158: 220/256
34	Fournie et al., (February 1995) "Plasma DNA as a marker of cancerous cell death. Investigation in patients suffering from lung cancer and in nude mice bearing human tumours." <i>Cancer Letters</i> , 91: 221-227

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY</b> <b>APPLICANT</b>	<b>Atty. Docket No.</b> 97,078-O	<b>Serial No.</b> 10/646,397
	<b>Applicant: Gocke et al.</b>	
	<b>Filing Date:</b> 08/22/2003	<b>Group: 1637</b>

35	Fowke et al., (1995) "Genetic analysis of human DNA recovered from minute amounts of serum of plasma." <i>Journal of Immunological Methods</i> , 180, pp. 45-51.
36	Gocke et al., "p53 and APC Mutations are Detectable in the Plasma and Serum of Patients with Colorectal Cancer (CRC) or Adenomas," <i>Annals New York Academy of Sciences</i> , p 44-50.
37	Gocke et al., "Serum BCL2/IGH DNA in Follicular Lymphoma Patients: A Minimal Residual Disease Marker," <i>Leukemia and Lymphoma</i> 2000, 39 (1-2) pp. 165-172.
38	Greenblatt et al., (1994) "Mutations in the p53 Tumor Suppressor Gene: Clues to Cancer Etiology and Molecular Pathogenesis." <i>Cancer Research</i> , 54:4855-4878
39	Hamilton, Stanley., (September 1992) "Molecular Genetics of Colorectal Carcinoma." <i>Cancer Supplement</i> , Vol. 70, No. 5, pp.1216-1221
40	Hollstein et al., (1994) "Database of p53 gene somatic mutations in human tumors and cell lines." <i>Nucleic Acids Research</i> , Vol. 22, No. 17, pp. 3551-3555
41	Juckett et al., (September 1982) "Actions of cis-Diamminedichloroplatinum on Cell Surface Nucleic Acids in Cancer Cells as Determined by Cell Electrophoresis Techniques." <i>Cancer Research</i> , 42: 3565-3573
42	Kahn et al., (1991) "Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification." <i>Oncogene</i> , 6: 1079-1083
43	Kamm et al., (1972) "Nucleic Acid Concentrations in Normal Human Plasma." <i>Clinical Chemistry</i> , Vol. 18, No. 6, pp. 519-522
44	Karet et al., (1994) "Quantification of mRNA in Human Tissue Using Fluorescent Nested Reverse-Transcriptase Polymerase Chain Reaction." <i>Analytical Biochemistry</i> , 220: 384-390
45	Kievits et al., (1991) "NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection." <i>Journal of Virological Methods</i> , 35: 273-286
46	Kimura et al., 1991, <i>J. Infect Dis.</i> 164:289-293
47	Kopreski et al., Somatic Mutation Screening: Identification of Individuals Harboring K-ras Mutations with the Use of Plasma DNA," <i>Journal of the National Cancer Institute</i> , vol. 92, no. 11, June 7, 2000.
48	Kondo et al., (March 1994) "Detection of Point Mutations in the K-ras Oncogene at Codon 12 in Pure Pancreatic Juice for Diagnosis of Pancreatic Carcinoma." <i>Cancer</i> , Vol. 23, No. 6, pp.1589-1594

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
97,078-O

Serial No.  
10/646,397

INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT

Applicant: Gocke et al.

Filing Date:  
08/22/2003

Group: 1637

49	Landergren Trends or Genetics 9:199-204, June 1993.
50	Landgraf et al., (1991) "Direct Analysis of Polymerase Chain Reaction Products Using Enzyme-linked Immunosorbent Assay Techniques." <i>Analytical Biochemistry</i> , 198:86-91
51	Landgraf et al., (1991) "Quantitative Analysis of Polymerase Chain Reaction (PCR) Products Using Primers Labeled with Biotin and a Fluorescent Dye." <i>Analytical Biochemistry</i> , 193: 231-235.
52	Lefort et al., "Point mutations of the K-Ras gene present in the DNA of colorectal tumors are found in the blood plasma DNA of the patients," <i>Proceedings of the American Association for Cancer Research Annual</i> . 36:557, 1995.
53	Leon et al., (1981) "A Comparison of DNA and DNA-Binding Protein Levels in Malignant Disease." <i>Europ. J. Cancer</i> , Vol. 17, No. 5, pp. 533-538
54	Leon et al., (March 1977) "Free DNA in the Serum of Cancer Patients and the Effect of Therapy." <i>Cancer Research</i> , 37: 646-650
55	Lowy et al., (November 1991) "Regulation of p21ras Activity." <i>Trends of Genetics</i> , 7: 346-351
56	Martin et al., (1992) "A Method for Using Serum of Plasma as a Source of DNA or HLA Typing." <i>Human Immunology</i> , 33: 108-113
57	Mayall et al., <i>J. Clin. Pathol.</i> 1998, 51:611-613
58	Mulcahy et al., (September 1996) "Cancer and mutant DNA in blood plasma." <i>Science</i> , Vol. 348, pp. 628.
59	Mulcany et al., "A Prospective Study of K-ras Mutations in the Plasma of Pancreatic Cancer Patients," <i>Clinical Cancer Research</i> , 4:271-5 (February 1998).
60	Nawroz et al., (September 1996) "Microsatellite alterations in serum DNA of head and neck cancer patients." <i>Nature Medicine</i> , Vol. 2, No. 9, pp. 1035-1037
61	Nelson et al., (February 1996) "Detection of K-ras gene mutations in non-neoplastic and lung cancers," <i>Cancer Letters</i> 103 (1996) 115-121 lung tissue
62	Olsen et al., 1996, <i>Int. J. Cancer</i> 68:415-419
63	Oudejans et al., (1991) "Differential Activation of RAS Genes By Point Mutation In Human Colon Cancer With Metastases To Either Lung of Liver." <i>Int. J. Cancer</i> , 49: 875-879

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Atty. Docket No.</b> 97,078-O	<b>Serial No.</b> 10/646,397
	<b>Applicant: Gocke et al.</b>			
	<b>Filing Date:</b> 08/22/2003		<b>Group: 1637</b>	

64	Pellegata et al., (1992) "Detection of K-ras Mutations by Denaturing Gradient Gel Electrophoresis (DGGE): A Study of Pancreatic Cancer." <i>Anticancer Research</i> , 12:1731-1736
65	Pourzand et al. Mutation Research 288:113-121, July 1993
66	Rex et al., Gastroenterology 1997; 11:24-28
67	Rhodes et al., (1995) "PCR-Detection of Tumor-Derived p53 DNA in Cerebrospinal Fluid." <i>Am. J. Clin. Path.</i> , 103:404-408
68	Shapiro et al., (June 1983) "Determination of Circulating DNA Levels in Patients with Benign or Malignant Gastrointestinal Disease." <i>Cancer</i> , Vol. 51, No. 11, pp.2116-2120
69	Shirasawa et al., (April 1993) "Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki-ras." <i>Science</i> , Vol. 260, pp.85-88
70	Sidransky, et al., (1992) "Identification of ras Oncogene Mutations in the Stool of Patients with Curable Colorectal Tumors." <i>Science</i> , Vol. 256, pp. 102-105.
71	Sidransky et al., "What we know and what we need to learn," Annals new York Academy of Sciences, pp1-4.
72	Sorenson et al., (January 1994) "Soluble Normal and Mutated DNA Sequence from Single-Copy Genes in Human Blood." <i>Cancer Epidemiology, Biomarkers &amp; Prevention</i> , Vol. 3, pp. 67-71.
73	Sorenson et al., Detection of Mutated KRAS2 Sequences as Tumor Markers in Plasma/Serum of Patients with Gastrointestinal Cancer, <i>Clinical Cancer Research</i> , 6:2129-37 (June 2000).
74	Stork et al., (1991) "Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction." <i>Oncogene</i> , 6: 857-862
75	Stroun et al., (1986) "Isolation and Characterization of DNA from the Plasma of Cancer Patients." <i>European Journal of Cancer</i> , Vol. 23, No. 6, pp. 707-712
76	Stroun et al., (1989) "Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients." <i>Oncology</i> , 46: 318-322
77	Tada et al., (June 1993) "Detection of ras Gene Mutations in Pancreatic Juice and Peripheral Blood of Patients with Pancreatic Adenocarcinoma." <i>Cancer Research</i> , 53:2472-2474
78	Taylor et al., (Date Unknown) "Shedding of Plasma Membrane Fragements. Neoplastic and Developmental Importance." <i>Membrane Fragment Shedding</i> , Chapter 3, pp. 33-57

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
97,078-O

Serial No.  
10/646,397

INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT

Applicant: Gocke et al.

Filing Date:  
08/22/2003

Group: 1637

79	Tseng et al., 1999, J. Clin. Oncol. 17:1391-1396
80	Urdea et al., (1991) "Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses." <i>Nucleic Acids Research</i> , Symposium Series No. 24, pp. 197-200
81	Urdea et al., (1993) "Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. <i>Aids</i> , 7 (suppl. 2): S11-S14
82	Vandamme et al., (1995) "Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR." <i>Journal of Virological Methods</i> , 52:121-132.
83	Van Mansfeld et al., "PCR-based Approaches for Detection of Mutated ras Genes," PCR Methods and Applications, pages 211-216.
84	Vasioukhin et al., (1994) "Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome of acute myelogenous leukaemia." <i>British Journal of Haematology</i> , 86: 774-779
85	Vasyukhin et al., (Date Unknown) "K-Ras Point Mutations in the Blood Plasma DNA of Patients with Colorectal Tumors."
86	Vogelstein et al., (September 1988) "Genetic Alterations During Colorectal-Tumor Development." <i>The New England Journal of Medicine</i> , Vol. 319, No. 9, pp. 525-532
87	Wang et al., (December 1989) "Quantitation of mRNA by the polymerase chain reaction." <i>Proc. Natl. Acad. Sci.</i> , Vol. 86, pp. 9717-9721
88	Winawer et al., The New-Eng. Journal of Medicine Volume 328, Number 13:901-906
89	Yamagata et al., (February 1994) "Lower Incidence of K-ras Codon 12 Mutation in Flat Colorectal Adenomas than in Polypoid Adenomas." <i>Jpn. J. Cancer Res.</i> , 85: 147-151

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.